Nord Anglia Education Soars on First Day of Trading; DirecTV Moves Higher on Dish Merger Talks

Follow this company

Companies Mentioned

03/27/2014 [ACCESSWIRE]

Nord Anglia Education Inc. (NYSE: NORD) – For an in-depth report on Nord Anglia Education Inc. follow:  

Nord Anglia Education closed up 12.50% on nearly 13.7 million shares traded. The stock was one of the biggest gainers on the NYSE and hit a high of $18.69 during intra-day trading. This was the first day of trading for the Hong Kong-based school operator after its IPO. Nord Anglia, which operates 27 schools in China, Southeast Asia, North America, Europe, and the Middle East, sold 19 million shares at $16 a share, the midpoint of its price range, to raise approximately $304 million in the IPO.

DIRECTV (NASDAQ: DTV) - For an in-depth report on DIRECTV follow:

Shares of DIRECTV closed up 5.70% on about 13.5 million shares traded on Wednesday. The stock’s gains were influenced by Dish Chairman Charlie Ergen recently approaching DirecTV for a possible merger as a strategic response to Comcast's proposal to buy Time Warner Cable that was announced last month, the report said, citing "several people with knowledge of the matter." Both companies however declined to comment on the report.

Primco Management Inc. (OTCBB: PMCM) - For an in-depth report on Primco Management Inc. follow:

Shares of PMCM closed up 12.77% on Wednesday with nearly 1.2 billion shares traded. The stock was one of the most active stocks in the OTCBB marketplace. Earlier in the week the company announced that it has commenced audits on both the Top Sail and D&B acquisitions, and that there will be no increase in the number of authorized shares until the audits and amended filing has been declared effective.

Keryx Biopharmaceuticals Inc. (NASDAQ: KERX) - For an in-depth report on Keryx Biopharmaceuticals Inc. follow:

Shares of KERX closed up 17.39% on Wednesday with nearly 16.5 million shares traded. The stock was one of the biggest gainers on the NASDAQ and even hit a new yearly high of $17.29 during intra-day trading. The stock’s gains may have been influenced by a rumor reported by, that the Centers for Medicare and Medicaid Services may delay its decision to move oral-only end-stage renal disease drugs into the ESRD bundle until 2024.


Disclosure: is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. Please read our report and visit our website, for complete risks and disclosures.


Leave a comment...

Your Name